euro adhoc: Intercell AG / quarterly or semiannual financial statement / Full year 2007 expected to be profitable - All development programs on track - Strong strategic and financial position due to s

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

6-month report

13.08.2007

Vienna (Austria), August 13, 2007 - Today Intercell AG (VSE: ICLL)
announced the financial results for H1 2007 and an update on the
company´s development programs and strategy.

Clear strategy to market for the first product - Intercell´s Japanese
Encephalitis vaccine

» All clinical studies supporting the licensure applications for US,
EU and Australia completed » US regulatory filing initiated - full
BLA submission expected in H2 2007 - expected approval H1 2008 »
Pediatric Phase II clinical trial in India started - results expected
for end 2007

World-leading franchise in Nosocomial Infections

» S.aureus vaccine partnered with Merck&Co - Phase II expected to
start in H2 2007 » Pseudomonas vaccine - start of Phase II/III
targeting intensive care unit patients planned for H1 2008

Hepatitis C vaccine - Phase II "proof-of-concept" study

» Interim results of approximately 25 study participants expected for
August 2007

Broadening the use of novel vaccine adjuvant - Intercell´s IC31®

» Phase I trial for Influenza vaccine adjuvanted with IC31® started -
recruitment completed - results expected for early 2008

Strategic partnership with Novartis (closed July 2, 2007)

» Intercell to receive EUR 270 million in upfront payments and equity
investment
» 4.8 million new shares at a share price of EUR 31.25
» exclusive Partnership for IC31® in influenza vaccines
» co-development in HCV therapeutic vaccines
» certain options for not-partnered vaccine candidates to Novartis
» closing of the transaction expected in Q3 2007

Solid financial and strong strategic position for further growth

» EUR 15.6 million net loss for H1 2007, up 26.7 percent as compared
to H1 2006 - reflecting R&D and manufacturing capacity increase »
Strong cash position with EUR 81.1 million in liquid funds at June
30, 2007 » Liquid funds expected to be approximately EUR 300 million
at the end of 2007 » Full year 2007 expected to be first profitable
year in company history, based on revenues from technology based
strategic product alliances

"According to plan our increased net loss in the first half of 2007
mainly results from higher R&D and manufacturing spending. However,
we expect to recognize revenues of approximately EUR 50 million this
year. This would make 2007 the first profitable year in the young
history of our company. After completion of the recently signed
agreement with Novartis, we expect to end the year with a cash
balance of approximately EUR 300 million," states Intercell´s CFO
Werner Lanthaler.

"Our strategy and highest priority is to maintain and to extend our
leading role as most innovative biotech company in the field of
vaccines and anti-infective antibodies," states Gerd Zettlmeissl, CEO
of Intercell.

The full half-year report is available at the executive offices of
Intercell AG, Campus Vienna Biocenter 6, 1030 Vienna or at
www.intercell.com.

end of announcement euro adhoc 13.08.2007 06:54:04
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Astrid Meinl
Corporate Communications
Tel. +43 1 20620-313
ameinl@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market